Cite
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study
MLA
Pappo, Alberto S., et al. “A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-like Growth Factor-1 Receptor (IGF-1R), in Patients with Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration Study.” Cancer (0008543X), vol. 120, no. 16, Aug. 2014, pp. 2448–56. EBSCOhost, https://doi.org/10.1002/cncr.28728.
APA
Pappo, A. S., Vassal, G., Crowley, J. J., Bolejack, V., Hogendoorn, P. C. W., Chugh, R., Ladanyi, M., Grippo, J. F., Dall, G., Staddon, A. P., Chawla, S. P., Maki, R. G., Araujo, D. M., Geoerger, B., Ganjoo, K., Marina, N., Blay, J., Schuetze, S. M., Chow, W. A., & Helman, L. J. (2014). A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer (0008543X), 120(16), 2448–2456. https://doi.org/10.1002/cncr.28728
Chicago
Pappo, Alberto S., Gilles Vassal, John J. Crowley, Vanessa Bolejack, Pancras C. W. Hogendoorn, Rashmi Chugh, Marc Ladanyi, et al. 2014. “A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-like Growth Factor-1 Receptor (IGF-1R), in Patients with Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration Study.” Cancer (0008543X) 120 (16): 2448–56. doi:10.1002/cncr.28728.